294 related articles for article (PubMed ID: 28330852)
1. A controlled-release mitochondrial protonophore reverses hypertriglyceridemia, nonalcoholic steatohepatitis, and diabetes in lipodystrophic mice.
Abulizi A; Perry RJ; Camporez JPG; Jurczak MJ; Petersen KF; Aspichueta P; Shulman GI
FASEB J; 2017 Jul; 31(7):2916-2924. PubMed ID: 28330852
[TBL] [Abstract][Full Text] [Related]
2. Controlled-release mitochondrial protonophore reverses diabetes and steatohepatitis in rats.
Perry RJ; Zhang D; Zhang XM; Boyer JL; Shulman GI
Science; 2015 Mar; 347(6227):1253-6. PubMed ID: 25721504
[TBL] [Abstract][Full Text] [Related]
3. Controlled-release mitochondrial protonophore (CRMP) reverses dyslipidemia and hepatic steatosis in dysmetabolic nonhuman primates.
Goedeke L; Peng L; Montalvo-Romeral V; Butrico GM; Dufour S; Zhang XM; Perry RJ; Cline GW; Kievit P; Chng K; Petersen KF; Shulman GI
Sci Transl Med; 2019 Oct; 11(512):. PubMed ID: 31578240
[TBL] [Abstract][Full Text] [Related]
4. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy.
Petersen KF; Oral EA; Dufour S; Befroy D; Ariyan C; Yu C; Cline GW; DePaoli AM; Taylor SI; Gorden P; Shulman GI
J Clin Invest; 2002 May; 109(10):1345-50. PubMed ID: 12021250
[TBL] [Abstract][Full Text] [Related]
5. Response to Pioglitazone in Patients With Nonalcoholic Steatohepatitis With vs Without Type 2 Diabetes.
Bril F; Kalavalapalli S; Clark VC; Lomonaco R; Soldevila-Pico C; Liu IC; Orsak B; Tio F; Cusi K
Clin Gastroenterol Hepatol; 2018 Apr; 16(4):558-566.e2. PubMed ID: 29223443
[TBL] [Abstract][Full Text] [Related]
6. Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions.
Cusi K
Diabetologia; 2016 Jun; 59(6):1112-20. PubMed ID: 27101131
[TBL] [Abstract][Full Text] [Related]
7. The indole derivative NecroX-7 improves nonalcoholic steatohepatitis in ob/ob mice through suppression of mitochondrial ROS/RNS and inflammation.
Chung HK; Kim YK; Park JH; Ryu MJ; Chang JY; Hwang JH; Lee CH; Kim SH; Kim HJ; Kweon GR; Kim KS; Shong M
Liver Int; 2015 Apr; 35(4):1341-53. PubMed ID: 25443620
[TBL] [Abstract][Full Text] [Related]
8. The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease.
Maximos M; Bril F; Portillo Sanchez P; Lomonaco R; Orsak B; Biernacki D; Suman A; Weber M; Cusi K
Hepatology; 2015 Jan; 61(1):153-60. PubMed ID: 25145475
[TBL] [Abstract][Full Text] [Related]
9. Reversal of hypertriglyceridemia, fatty liver disease, and insulin resistance by a liver-targeted mitochondrial uncoupler.
Perry RJ; Kim T; Zhang XM; Lee HY; Pesta D; Popov VB; Zhang D; Rahimi Y; Jurczak MJ; Cline GW; Spiegel DA; Shulman GI
Cell Metab; 2013 Nov; 18(5):740-8. PubMed ID: 24206666
[TBL] [Abstract][Full Text] [Related]
10. Lipodystrophy Due to Adipose Tissue-Specific Insulin Receptor Knockout Results in Progressive NAFLD.
Softic S; Boucher J; Solheim MH; Fujisaka S; Haering MF; Homan EP; Winnay J; Perez-Atayde AR; Kahn CR
Diabetes; 2016 Aug; 65(8):2187-200. PubMed ID: 27207510
[TBL] [Abstract][Full Text] [Related]
11. A subset of patients with acquired partial lipodystrophy developing severe metabolic abnormalities.
Ozgen Saydam B; Sonmez M; Simsir IY; Erturk MS; Kulaksizoglu M; Arkan T; Hekimsoy Z; Cavdar U; Akinci G; Demir T; Altay CT; Mihci E; Secil M; Akinci B
Endocr Res; 2019; 44(1-2):46-54. PubMed ID: 30182761
[TBL] [Abstract][Full Text] [Related]
12. The liver diseases of lipodystrophy: the long-term effect of leptin treatment.
Safar Zadeh E; Lungu AO; Cochran EK; Brown RJ; Ghany MG; Heller T; Kleiner DE; Gorden P
J Hepatol; 2013 Jul; 59(1):131-7. PubMed ID: 23439261
[TBL] [Abstract][Full Text] [Related]
13. Ectopic lipid deposition mediates insulin resistance in adipose specific 11β-hydroxysteroid dehydrogenase type 1 transgenic mice.
Abulizi A; Camporez JP; Zhang D; Samuel VT; Shulman GI; Vatner DF
Metabolism; 2019 Apr; 93():1-9. PubMed ID: 30576689
[TBL] [Abstract][Full Text] [Related]
14. Roux-en-y gastric bypass attenuates hepatic mitochondrial dysfunction in mice with non-alcoholic steatohepatitis.
Verbeek J; Lannoo M; Pirinen E; Ryu D; Spincemaille P; Vander Elst I; Windmolders P; Thevissen K; Cammue BP; van Pelt J; Fransis S; Van Eyken P; Ceuterick-De Groote C; Van Veldhoven PP; Bedossa P; Nevens F; Auwerx J; Cassiman D
Gut; 2015 Apr; 64(4):673-83. PubMed ID: 24917551
[TBL] [Abstract][Full Text] [Related]
15. Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy.
Javor ED; Ghany MG; Cochran EK; Oral EA; DePaoli AM; Premkumar A; Kleiner DE; Gorden P
Hepatology; 2005 Apr; 41(4):753-60. PubMed ID: 15791619
[TBL] [Abstract][Full Text] [Related]
16. Emerging Pharmacological Targets for the Treatment of Nonalcoholic Fatty Liver Disease, Insulin Resistance, and Type 2 Diabetes.
Goedeke L; Perry RJ; Shulman GI
Annu Rev Pharmacol Toxicol; 2019 Jan; 59():65-87. PubMed ID: 30625285
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological management of nonalcoholic fatty liver disease in type 2 diabetes.
Cernea S; Cahn A; Raz I
Expert Rev Clin Pharmacol; 2017 May; 10(5):535-547. PubMed ID: 28276774
[TBL] [Abstract][Full Text] [Related]
18. 20 years of leptin: leptin in common obesity and associated disorders of metabolism.
DePaoli AM
J Endocrinol; 2014 Oct; 223(1):T71-81. PubMed ID: 24973357
[TBL] [Abstract][Full Text] [Related]
19. Metreleptin therapy for nonalcoholic steatohepatitis: Open-label therapy interventions in two different clinical settings.
Akinci B; Subauste A; Ajluni N; Esfandiari NH; Meral R; Neidert AH; Eraslan A; Hench R; Rus D; McKenna B; Hussain HK; Chenevert TL; Tayeh MK; Rupani AR; Innis JW; Mantzoros CS; Conjeevaram HS; Burant CL; Oral EA
Med; 2021 Jul; 2(7):814-835. PubMed ID: 35291351
[TBL] [Abstract][Full Text] [Related]
20. Prevention and reversal of lipotoxicity-induced hepatic insulin resistance and steatohepatitis in mice by an antioxidant carotenoid, β-cryptoxanthin.
Ni Y; Nagashimada M; Zhan L; Nagata N; Kobori M; Sugiura M; Ogawa K; Kaneko S; Ota T
Endocrinology; 2015 Mar; 156(3):987-99. PubMed ID: 25562616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
